Nonprofit · EIN 87-1920284
ARC RESEARCH INSTITUTE
Tax-exempt · PALO ALTO, CA 94304
Financials
| Year ended | Form | Revenue | Expenses | Net income | Total assets | Liabilities | Net assets |
|---|---|---|---|---|---|---|---|
| December 31, 2024 | 990 | $122,280,682 | $82,781,856 | $39,498,826 | $184,388,461 | $83,668,141 | $100,720,320 |
| December 31, 2023 | 990 | $53,611,444 | $64,203,698 | -$10,592,254 | $155,698,196 | $93,814,180 | $61,884,016 |
Financial details: 990 for the year ended December 31, 2024
Revenue
- Contributions, gifts and grants
- $120,446,690
- Program service revenue
- $166,647
- Investment income
- $1,667,345
- Other revenue
- $0
Expenses
- Grants and similar amounts paid
- $11,262,833
- Compensation of officers, directors and key employees
- $4,448,861
- Other salaries and wages
- $15,997,400
- Salaries, compensation and benefits (total)
- $24,229,467
- Professional fundraising fees
- $0
- Legal fees
- $1,099,139
- Accounting fees
- $73,383
- Occupancy
- $15,373,698
- Travel
- $580,682
- Depreciation
- $10,104,678
- Program services (functional)
- $64,083,480
- Management and general (functional)
- $18,698,376
Balance sheet and other
- Total assets, start of year
- $155,698,196
- Total assets, end of year
- $184,388,461
- Total liabilities, end of year
- $83,668,141
- Net assets, end of year
- $100,720,320
- Land, buildings and equipment
- $86,376,957
- Net assets without donor restrictions
- $100,720,320
- Gross receipts
- $122,280,682
- Employees
- 155
- Volunteers
- 12
- Year formed
- 2021
- State of legal domicile
- DE
From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.
Officers, directors and key employees
As listed on the 990 for the year ended December 31, 2024, highest compensation first.
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| Alden J Woodrow | CHIEF OPERATING OFFICER Officer | 40 | $1,141,800 | $75,116 |
| Julia M Kazaks | GENERAL COUNSEL/ SECRETARY Officer | 40 | $478,739 | $71,128 |
| Patrick D Hsu PhD | Core Investigator/ Co-Founder Officer | 40 | $489,195 | $39,441 |
| Yusuf H Roohani PHD | Group lead, machine learning Highest-paid employee | 40 | $407,429 | $37,342 |
| Lynn M Hendrickson | UNIVERSITY RELATIONS & ACADEMIC AFFAIRS/ COMPLIANCE OFFICER Officer | 40 | $344,044 | $74,771 |
| Nianzhen Li PHD | Senior Director, Multi-omics technology development Highest-paid employee | 40 | $391,440 | $8,602 |
| Therese A Costello | Head of People Officer | 40 | $352,151 | $7,913 |
| Lingyin Li PHD | Core Investigator Highest-paid employee | 40 | $333,725 | $24,081 |
| Nicolle D Seuss | Senior Operations Program Manager Officer | 40 | $290,334 | $52,106 |
| Hani Goodarzi PHD | CORE INVESTIGATOR Highest-paid employee | 40 | $273,663 | $46,901 |
| Luke A Gilbert PHD | CORE INVESTIGATOR Highest-paid employee | 40 | $262,408 | $32,129 |
| Silvana M Konermann PhD | EXECUTIVE DIRECTOR/ PRESIDENT Officer | 40 | $245,574 | $18,972 |
| Susan T Cull | SENIOR FINANCE MANAGER Officer | 40 | $189,233 | $9,893 |
| Michael K Teng | HEAD OF FINANCE/ TREASURER (AS OF 7/01/2024) Officer | 40 | $151,006 | $37,111 |
| Rose E Harris | Finance (until 7/15/24) Officer | 40 | $127,201 | $262 |
5 more people on this return
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| Dave Burke | Chief Technology Officer (as of 10/31/2024) Officer | 40 | $65,712 | $10,401 |
| Daniel P Dever PhD | Head of Scientific Operations (until 1/26/24) Officer | 40 | $62,998 | $5,760 |
| Nathaniel Friedman | Director Trustee or director | 1 | $36,000 | $0 |
| Reid Hoffman | Director Trustee or director | 1 | $36,000 | $0 |
| Susan Li | Director Trustee or director | 1 | $36,000 | $0 |
990 for the year ended December 31, 2023: 16 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| Alden J Woodrow | COO Officer | 40 | $742,239 | $35,102 |
| Patrick D Hsu PhD | Core Investigator Officer | 40 | $504,392 | $19,740 |
| Julia M Kazaks | General Counsel Officer | 40 | $365,174 | $25,698 |
| Jennifer A Moss | Senior Recruiter Highest-paid employee | 40 | $341,470 | $16,098 |
| Lynn M Hendrickson | University Relations & Academic Affairs Officer | 40 | $338,360 | $14,205 |
| Luke Gilbert | CORE INVESTIGATOR Highest-paid employee | 40 | $279,098 | $15,338 |
| Nicolle D Seuss | Senior Operations Program Manager Officer | 40 | $270,911 | $20,678 |
| Lingyin Li | Core Investigator Highest-paid employee | 40 | $283,866 | $6,358 |
| Benjamin N Mijts | Senior Director, Genome Engineering Technology Center Highest-paid employee | 40 | $259,934 | $20,285 |
| Nianzhen Li PHD | Senior Director, Multi-omics technology development Highest-paid employee | 40 | $274,094 | $4,096 |
| Silvana M Konermann PhD | Executive Director Officer | 40 | $225,268 | $1,418 |
| Susan Cull | Senior Finance Officer | 40 | $156,004 | $7,572 |
| Therese Costello | Head of People Officer | 40 | $146,619 | $6,311 |
| Rose E Harris | Finance Officer | 40 | $151,655 | $0 |
| Daniel Dever PhD | Head of Scientific Operations Officer | 40 | $117,098 | $8,809 |
| Nathaniel Friedman | Secretary/Director Trustee or director | 1 | $36,000 | $0 |
Address and contacts
- Address (IRS master file)
- 3181 PORTER DR, PALO ALTO, CA 94304-1213
- Principal officer (990 for 2024)
- SILVANA M KONERMANN PHD, 3181 Porter Dr, Palo Alto, CA 943041249
- Signed the 990
- SILVANA M KONERMANN, EXECUTIVE DIRECTOR
- Phone
- (650) 899-4880
- Website
- https://arcinstitute.org/
- Return prepared by
- CROWE LLP
Mission
Our mission is to accelerate scientific progress, understand the root causes of disease, and narrow the gap between discoveries and impact on patients.
Program accomplishments
- - Core Investigators (which include the following labs) are provided with no-strings-attached, multi-year funding as well as cutting-edge scientific and infrastructure support to enable high-risk, high-reward science. They are innovative pioneers enabled to pursue their very best ideas. The Gilbert lab has an expertise in synthetic biology, functional genomics and cancer biology. We build CRISPR epigenetic editing tools to turn genes on and off and to perturb gene regulatory elements. We are developing CRISPR functional genomics approaches to map individual genes or sets of genes that regulate phenotypes of interest in vitro and in vivo. We are focused on utilizing our expertise to tackle big problems in deadly human cancers such as metastasis and drug resistance. The Hsu Lab works at the intersection of synthetic biology and genomics to invent new biotechnologies for improving human health. The Konermann lab develops and applies next-generation functional genomics to understand the cellular and molecular pathways underlying the neuronal system and neurodegenerative disease, with the long-term goal of developing rationally targeted therapeutics for neurodegenerative disorders. The Li Lab combines chemistry, biochemistry, immunology, and physiology to uncover basic mechanisms in innate immunity and, in parallel, develop therapeutic hypotheses and lead molecules. Innate immune pathways as the first line of defense against pathogens present many exciting opportunities for scientists from many disciplines. These pathways are a rich source of novel chemistry: they involve diverse molecular patterns in pathogens, little-explored second messengers, and drugs with poorly understood mechanism. Activation of innate immunity is a proven therapeutic strategy for vaccination, viral infection, and cancer, while inhibition is a strategy for treating autoimmune diseases and neurodegeneration. To date, however, most modulators of innate immunity are broad, non-specific, and poorly characterized, such as killed bacteria, alum crystals, and steroids. The Li lab seeks to improve understanding of these pathways and facilitate the development of more precise drugs for preventing or treating specific diseases. The Horns Lab creates and uses new technologies to understand and manipulate cells. We aim to discover the fundamental principles governing how cells and tissues operate, and to harness these insights to improve human health. Our work unites molecular engineering, synthetic biology, and genomics to answer questions and solve problems in immunology, neuroscience, cancer, and aging. The Goodarzi Lab combines modern experimental and computational technologies to understand complex human diseases at a molecular level. We are predominantly focused on metastatic progression in multiple cancers and neurodegenerative diseases as the biggest challenges to human health in the 21st century. - Technology Development Centers As biomedical research has become more advanced, it has become more dependent on complicated tooling that is difficult or impossible for any single lab to pursue today. Arc Technology Centers are focused on advancing and distributing key biomedical technologies within the institute that require high capital scale, targeted expertise, and systematic innovation. Our Technology Centers provide long-term career options for Arc scientists beyond their training period. By enabling competitive compensation relative to the biotech and tech industries (such as for research scientists and computer programmers), our goal is to expand the ecosystem of available career paths in research and maintain continuity in critical technical know-how. We have 5 staffed Technology Centers focused on 1. Cellular Models 2. Genome Engineering 3. Mammalian Models 4. Multi-omics 5. Computational biology - Translational Programs Making an impact on complex diseases requires new fundamental biological insights into disease mechanisms and new technologies that can target rational therapeutic pathways at the right place and time in the body. In addition to curiosity-driven knowledge building, producing medically useful discoveries is a core mission of Arc. Arc will build translational infrastructure to support the distribution of new biological insights and biotechnologies into the clinical environment. This branch of the institute will be dedicated to reducing the friction of transferring academic research into for-profit spin-outs. This includes a streamlined IP licensing process, funding support, and an advisory network of drug development and domain experts. We will also create focused, entrepreneurial teams dedicated to testing specific ideas, such as a new gene target or effector molecule, within the institute. Our goal is to empower Arc scientists, engineers, and inventors to accelerate their work into impact on patients.Expenses $64,083,480 · grants $11,262,833 · revenue $166,647
What it must file and when
IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.
| Tax year | Year ended | Due | IRS public records |
|---|---|---|---|
| 2025 | December 31, 2025 | May 15, 2026 | Not on file |
| 2024 | December 31, 2024 | May 15, 2025 | 990 on file |
| 2023 | December 31, 2023 | May 15, 2024 | 990 on file |
IRS record
- EIN
- 87-1920284
- Tax-exempt status
- 501(c)(3): Charitable, religious, educational or scientific organization
- Foundation status
- Hospital or medical research organization
- Donations deductible (Pub 78)
- Public charity, 50% deduction limit
- Exempt since
- 2022
- Accounting year ends
- December
- Files
- Form 990 or 990-EZ
- Category (NTEE)
- Medical research (H99)
- Assets (IRS master file)
- $184,388,461
- Income (IRS master file)
- $122,280,682
Filing history
| Form | Year ended | Revenue | Expenses | Assets | Return |
|---|---|---|---|---|---|
| 990 | December 2024 | $122,280,682 | $82,781,856 | $184,388,461 | XML |
| 990 | December 2023 | $53,611,444 | $64,203,698 | $155,698,196 | XML |
| 990 | December 2022 | $96,576,028 | $32,795,122 | $150,115,619 | IRS |
| 990 | December 2021 | – | – | – | IRS |
990-N: the IRS publishes only the latest e-Postcard per organization; earlier years appear here as 990.tax collects the monthly files. 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS.
Questions about ARC RESEARCH INSTITUTE
- What is the EIN of ARC RESEARCH INSTITUTE?
- The employer identification number (EIN) of ARC RESEARCH INSTITUTE is 87-1920284.
- Is ARC RESEARCH INSTITUTE tax-exempt?
- Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 2022.
- Are donations to ARC RESEARCH INSTITUTE tax-deductible?
- Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
- Which annual return does ARC RESEARCH INSTITUTE file?
- Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
- When is the next return of ARC RESEARCH INSTITUTE due?
- The return for tax year 2025 (the year ending December 31, 2025) is due May 15, 2026. Form 8868 extends it by six months; the 990-N cannot be extended.
- When did ARC RESEARCH INSTITUTE last file with the IRS?
- The latest return in the IRS public files is the 990 for the year ended December 2024.
- Who is the principal officer of ARC RESEARCH INSTITUTE?
- The 990 for the year ended December 31, 2024 names SILVANA M KONERMANN PHD.
- Who are the officers and directors of ARC RESEARCH INSTITUTE?
- The 990 for the year ended December 31, 2024 lists 20 people; 20 received compensation from the organization, the highest $1,141,800 (Alden J Woodrow, CHIEF OPERATING OFFICER).
- How much revenue does ARC RESEARCH INSTITUTE have?
- On its 990 for the year ended December 31, 2024 it reported revenue of $122,280,682, expenses of $82,781,856 and total assets of $184,388,461 at year end.
Other nonprofits in PALO ALTO
- PALO ALTO VETERANS INSTITUTE FOR RESEARCH EIN 77-0207331 · last filed 990 for 2025
- CYSTIC FIBROSIS RESEARCH INSTITUTE EIN 51-0169988 · last filed 990 for 2024
- A FOUNDATION BUILDING STRENGTH INC EIN 26-1761329 · last filed 990 for 2024
- HARVEY BASSETT CLARKE FOUNDATION EIN 94-6104609 · last filed 990-EZ for 2025
- SCITON MEDICAL FOUNDATION EIN 92-2451235 · last filed 990 for 2025
- IRON HORSE FOUNDATION EIN 30-0841411 · last filed 990-N for 2025
- JEN-HSUN & LORI HUANG FOUNDATION EIN 26-1551239 · last filed 990-PF for 2024
- LUCILE SALTER PACKARD CHILDRENS HOSPITAL AT STANFORD EIN 77-0003859 · last filed 990 for 2025